Clinical Trials
250 trialsBuMelMCRN001
University Health Network, Toronto
TT4B
University of Arkansas
UARK 2008-02 A Trial for High-risk Myeloma Evaluating Accelerating and Sustaining Complete Remission
University of Arkansas
MASTER-2
University of Alabama at Birmingham
Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant
National Cancer Institute (NCI)
Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
National Cancer Institute (NCI)
A Study of Melphalan With or Without Siltuximab in People With Multiple Myeloma Having an Autologous Stem Cell Transplant
Memorial Sloan Kettering Cancer Center
Study of Thiotepa Combination With Melphalan (TM Protocol) Conditioning for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma:A Prospective Randomized Controlled Clinical Trial
First Affiliated Hospital Xi'an Jiaotong University
Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant
Roswell Park Cancer Institute
Lenalidomide Plus Melphalan as a Preparative Regimen for Autologous Stem Cell Transplantation in Relapsed Multiple Myeloma: A Phase 1 / 2 Study
Weill Medical College of Cornell University
Flu-Mel-Vel
Hackensack Meridian Health
IFM2012-03
University Hospital, Lille
Auto Transplant High Dose Melphalan vs High Dose Melphalan+Bortezomib in Pts With Multiple Myeloma Age 65 Years or Older
Hackensack Meridian Health
MMulti-Immune HR; Multi-Target Immunotherapy for High-Risk Multiple Myeloma
University of Arkansas
Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma
M.D. Anderson Cancer Center
Propylene Glycol-Free Melphalan HCl (EVOMELA®) in Combination With Fludarabine and Total Body Irradiation Based Reduced Intensity Conditioning for Haploidentical Transplantation
Medical College of Wisconsin
HO95
Stichting Hemato-Oncologie voor Volwassenen Nederland
Daratumumab After Stem Cell Transplant in Treating Patients With Multiple Myeloma
City of Hope Medical Center
STUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMA
University of Turin, Italy
Two Step Haplo With Radiation Conditioning
Thomas Jefferson University
High Dose Ascorbic Acid for Plasma Cell Disorders
University of Iowa
Umbilical Cord Blood Transplantation From Unrelated Donors
University of Rochester
2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy
University of Arkansas
Impact of Recombinant Human Interleukin-7 (CYT107) on Tumor Clearance and Immune Reconstitution in Multiple Myeloma Patients After Autologous Hematopoietic Cell Transplant
Washington University School of Medicine
A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma
Janssen Research & Development, LLC
Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders
City of Hope Medical Center
Melphalan and Radiation Therapy Followed By Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Stage I, Stage II, or Stage III Multiple Myeloma
City of Hope Medical Center
Personalized Autologous Transplant for Multiple Myeloma
Emory University
Umbilical Cord Blood-Derived Natural Killer Cells, Elotuzumab, Lenalidomide, and High Dose Melphalan, Followed by Stem Cell Transplant in Treating Patients With Multiple Myeloma
M.D. Anderson Cancer Center
Melphalan Hydrochloride in Treating Participants With Newly-Diagnosed Multiple Myeloma Undergoing Donor Stem Cell Transplantation
M.D. Anderson Cancer Center
A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens
Janssen Research & Development, LLC
A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma
Janssen Research & Development, LLC
Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma
City of Hope Medical Center
Dose Escalation Trial of WT1-specific Donor-derived T Cells Following T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed/Refractory Multiple Myeloma
Memorial Sloan Kettering Cancer Center
Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma
M.D. Anderson Cancer Center
BEB-2
Insel Gruppe AG, University Hospital Bern
Bortezomib-bendamustine-melphalan vs Melphalan for Multiple Myeloma
Uppsala University
BMT-03
University of Illinois at Chicago
Lenalidomide and Dexamethasone Versus Melphalan Prednisone and Lenalidomide Versus Cyclophosphamide, Prednisone and Lenalidomide in Elderly Multiple Myeloma Patients
Fondazione EMN Italy Onlus
Cyclophosphamide, Lenalidomide and Dexamethasone (CRD) Versus Melphalan (200 mg/m2) Followed By Autologous Stem Cell Transplant (ASCT) In Newly Diagnosed Multiple Myeloma Subjects
Fondazione EMN Italy Onlus
MPRvsMEL200
Fondazione EMN Italy Onlus
TreoMel
Insel Gruppe AG, University Hospital Bern
Evaluate Safety and Efficacy of High-dose Melphalan HCL for Injection in MM Patients With Auto-HSC Transplantation
CASI Pharmaceuticals (China) Co., Ltd.
MUKnineb
University of Leeds
Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401)
National Heart, Lung, and Blood Institute (NHLBI)
ASCT With Nivolumab in Patients With Multiple Myeloma
St. Petersburg State Pavlov Medical University
A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)
Janssen Research & Development, LLC
AHCT
Case Comprehensive Cancer Center
Enhancing Anti--Tetanus Vaccine Response After Autologous Stem Cell Transplantation
University of Nebraska